By July 2011, Locus Pharmaceuticals Inc had ceased operations. The firm had been a privately held drug discovery and development biotechnology company creating novel therapeutics using its patented drug design technology. Based on its platform technology, Locus had entered into multiple drug discovery collaboration projects with pharmaceutical partners - to include P&G Pharmaceuticals. IP licensed from Cornell - enabling them to build a pipeline of early drug development assets for cancer and inflammatory indications. In 2004 the firm had acquired fellow SBIR Awardee - small-molecule drug discovery start-up Protein Mechanics and raised capital from a ramge of known sources.
